Patents by Inventor David V. Goeddel
David V. Goeddel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7754858Abstract: The invention concerns antibodies to new tumor necrosis factor receptor associated factors, designated TRAF. The new factors are capable of specific association with the intracellular domain of the type 2 TNF receptor (TNF-R2), and are involved in the mediation of tumor necrosis factor (TNF) biological activities.Type: GrantFiled: June 7, 2007Date of Patent: July 13, 2010Assignee: Genentech, Inc.Inventors: David V. Goeddel, Mike Rothe
-
Patent number: 7528244Abstract: The invention provides methods and compositions relating to apoptosis regulating proteins, known as Casper proteins, and related nucleic acids. The proteins may be produced recombinantly from transformed host cells from the disclosed Casper encoding nucleic acid or purified from human cells. The invention provides specific hybridization probes and primers capable of specifically hybridizing with the disclosed Casper gene, Casper-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.Type: GrantFiled: May 18, 2001Date of Patent: May 5, 2009Assignee: Amgen, Inc.Inventors: Hong-Bing Shu, David V. Goeddel
-
Patent number: 7244836Abstract: The invention concerns new tumor necrosis factor receptor associated factors, designated TRAF. The new factors are capable of specific association with the intracellular domain of the type 2 TNF receptor (TNF-R2), and are involved in the mediation of TNF biological activities.Type: GrantFiled: October 30, 2002Date of Patent: July 17, 2007Assignee: Genentech, Inc.Inventors: David V. Goeddel, Mike Rothe
-
Patent number: 7029871Abstract: The invention relates to a human Receptor Interacting Protein (hRIP), nucleic acids which encode hRIP and methods of using the subject compositions; in particular, methods such as hRIP-based in vitro binding assays and phosphorylation assays for screening chemical libraries for lead compounds for pharmacological agents.Type: GrantFiled: January 9, 2001Date of Patent: April 18, 2006Assignee: Amgen, Inc.Inventors: Vijay R. Baichwal, Jianing Huang, Hailing Hsu, David V. Goeddel
-
Patent number: 6964765Abstract: The invention provides methods and compositions relating to novel human cellular inhibitor of apoptosis proteins (c-IAP1/2) comprising a series of defined structural domain repeats and/or a RING finger domain; in particular at least two of: a particular first domain repeat, a particular second domain repeat, and a particular third domain repeat, and/or a particular RING finger domain. The proteins provide a c-IAP specific function, with preferred proteins being capable of modulating the induction of apoptosis, for example, by binding a human tumor necrosis factor receptor associated factor (TRAF). The compositions include nucleic acids which encode the subject c-IAP and hybridization probes and primers capable of hybridizing with the disclosed c-IAP genes. The invention includes methods of using the subject compositions in therapy, in diagnosis and in the biopharmaceutical industry.Type: GrantFiled: September 3, 2004Date of Patent: November 15, 2005Assignee: Amgen, Inc.Inventors: Mike Rothe, David V. Goeddel
-
Patent number: 6855815Abstract: The invention provides methods and compositions relating to novel human cellular inhibitor of apoptosis proteins (c-IAP1/2) comprising a series of defined structural domain repeats and/or a RING finger domain; in particular, at least two of: a particular first domain repeat, a particular second domain repeat, and a particular third domain repeat, and/or a particular RING finger domain. The proteins provide a c-IAP specific function, with preferred proteins being capable of modulating the induction of apoptosis; for example, by binding a human tumor necrosis factor receptor associated factor (TRAF). The compositions include nucleic acids which encode the subject c-IAP and hybridization probes and primers capable of hybridizing with the disclosed c-IAP genes. The invention includes methods of using the subject compositions in therapy, in diagnosis and in the biopharmaceutical industry.Type: GrantFiled: August 30, 2002Date of Patent: February 15, 2005Assignee: Amgen Inc.Inventors: Mike Rothe, David V. Goeddel
-
Patent number: 6838550Abstract: The invention provides methods and compositions relating to Suppressor of Death Domain (SODD) proteins which regulate cellular signal transduction and transcriptional activation, and related nucleic acids. The polypeptides may be produced recombinantly from transformed host cells from the disclosed SODD encoding nucleic acids or purified from human cells. The invention provides isolated SODD hybridization probes and primers capable of specifically hybridizing with the disclosed SODD genes, SODD-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.Type: GrantFiled: May 30, 2002Date of Patent: January 4, 2005Assignee: Arngen Inc.Inventors: David V. Goeddel, Yingping Jiang
-
Patent number: 6821736Abstract: The invention provides methods and compositions relating to novel human cellular inhibitor of apoptosis proteins (c-IAP1/2) comprising a series of defined structural domain repeats and/or a RING finger domain; in particular, at least two of: a particular first domain repeat, a particular second domain repeat, and a particular third domain repeat, and/or a particular RING finger domain. The proteins provide a c-IAP specific function, with preferred proteins being capable of modulating the induction of apoptosis; for example, by binding a human tumor necrosis factor receptor associated factor (TRAF). The compositions include nucleic acids which encode the subject c-IAP and hybridization probes and primers capable of hybridizing with the disclosed c-IAP genes. The invention includes methods of using the subject compositions in therapy, in diagnosis and in the biopharmaceutical industry.Type: GrantFiled: October 12, 2000Date of Patent: November 23, 2004Assignee: Amgen Inc.Inventors: Mike Rothe, David V Goeddel
-
Patent number: 6822138Abstract: The present invention provides transgenic non-human mammals and cells having one or more structurally and functionally disrupted NIK alleles. In addition, the present invention provides methods for making such transgenic mammals and cells, and methods for determining the effect of a compound on an animal or cell that lacks NIK function. The present invention also provides methods for identifying compounds useful in the inhibition of osteoclastogenesis in a mammal, for example to treat osteoporosis or other conditions. Also provided are methods of modulating the extent of osteoclastogenesis in a cell or a mammal using NIK modulators.Type: GrantFiled: November 2, 2000Date of Patent: November 23, 2004Assignee: Washington University in St. LouisInventors: Robert D. Schreiber, David V. Goeddel, Steven L. Teitelbaum, Holger Wesche
-
Publication number: 20040087774Abstract: The invention concerns novel inhibitors of tumor necrosis factor receptor associated factor-(TRAF) mediated signal transduction. The invention encompasses the novel inhibitor proteins (I-TRAFs), nucleic acid encoding them, methods for their recombinant production, and their use in screening assays and as pharmaceuticals.Type: ApplicationFiled: October 3, 2003Publication date: May 6, 2004Applicant: Genentech, Inc.Inventors: David V. Goeddel, Mike Rothe
-
Patent number: 6673343Abstract: Agonist antibodies are disclosed which bind to the extracellular domain of receptor protein tyrosine kinases pTKs, and thereby cause dimerization and activation of the intracellular tyrosine kinase domain thereof. The antibodies are useful for activating their respective receptor and thereby enabling the role of the tyrosine kinase receptor in cell growth and/or differentiation to be studied. Chimeric proteins comprising the extracellular domain of the receptor pTKs and an immunoglobulin constant domain sequence are also disclosed.Type: GrantFiled: October 17, 2001Date of Patent: January 6, 2004Assignee: Genentech, Inc.Inventors: Brian D. Bennett, David V. Goeddel, James M. Lee, William Matthews, Siao Ping Tsai, William I. Wood
-
Publication number: 20030166193Abstract: The invention provides methods and compositions relating to Suppressor of Death Domain (SODD) proteins which regulate cellular signal transduction and transcriptional activation, and related nucleic acids. The polypeptides may be produced recombinantly from transformed host cells from the disclosed SODD encoding nucleic acids or purified from human cells. The invention provides isolated SODD hybridization probes and primers capable of specifically hybridizing with the disclosed SODD genes, SODD-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.Type: ApplicationFiled: May 30, 2002Publication date: September 4, 2003Inventors: David V. Goeddel, Yingping Jiang
-
Patent number: 6610830Abstract: Disclosed herein are methods and means of microbially producing, via recombinant DNA technology, mature human leukocyte interferons, useful in the treatment of viral and neoplastic diseases.Type: GrantFiled: April 21, 1981Date of Patent: August 26, 2003Assignees: Hoffman-La Roche Inc., Genentech, Inc.Inventors: David V. Goeddel, Sidney Pestka
-
Publication number: 20030143579Abstract: The invention provides methods and compositions relating to novel human cellular inhibitor of apoptosis proteins (c-IAP1/2) comprising a series of defined structural domain repeats and/or a RING finger domain; in particular, at least two of: a particular first domain repeat, a particular second domain repeat, and a particular third domain repeat, and/or a particular RING finger domain. The proteins provide a c-IAP specific function, with preferred proteins being capable of modulating the induction of apoptosis; for example, by binding a human tumor necrosis factor receptor associated factor (TRAF). The compositions include nucleic acids which encode the subject c-IAP and hybridization probes and primers capable of hybridizing with the disclosed c-IAP genes.Type: ApplicationFiled: August 30, 2002Publication date: July 31, 2003Applicant: Tularik, Inc.Inventors: Mike Rothe, David V. Goeddel
-
Publication number: 20030120043Abstract: The invention concerns new tumor necrosis factor receptor associated factors, designated TRAF. The new factors are capable of specific association with the intracellular domain of the type 2 TNF receptor (TNF-R2), and are involved in the mediation of TNF biological activities.Type: ApplicationFiled: October 30, 2002Publication date: June 26, 2003Applicant: Genentech, Inc.Inventors: David V. Goeddel, Mike Rothe
-
Patent number: 6500922Abstract: The invention concerns new tumor necrosis factor receptor associated factors, designated TRAF. The new factors are capable of specific association with the intracellular domain of the type 2 TNF receptor (TNF-R2), and are involved in the mediation of TNF biological activities.Type: GrantFiled: January 7, 1997Date of Patent: December 31, 2002Assignee: Genentech, Inc.Inventors: David V. Goeddel, Mike Rothe
-
Patent number: 6482613Abstract: Disclosed herein are methods and means of microbially producing, via recombinant DNA technology, mature human leukocyte interferons, useful in the treatment of viral and neoplastic diseases.Type: GrantFiled: January 19, 1988Date of Patent: November 19, 2002Assignees: Hoffmann-La Roche Inc., Genentech, Inc.Inventors: David V. Goeddel, Sidney Pestka
-
Publication number: 20020146420Abstract: Agonist antibodies are disclosed which bind to the extracellular domain of receptor protein tyrosine kinases pTKs, and thereby cause dimerization and activation of the intracellular tyrosine kinase domain thereof. The antibodies are useful for activating their respective receptor and thereby enabling the role of the tyrosine kinase receptor in cell growth and/or differentiation to be studied. Chimeric proteins comprising the extracellular domain of the receptor pTKs and an immunoglobulin constant domain sequence are also disclosed.Type: ApplicationFiled: October 17, 2001Publication date: October 10, 2002Applicant: Genentech, Inc.Inventors: Brian D. Bennett, David V. Goeddel, James M. Lee, William Matthews, Siao Ping Tsai, William I. Wood
-
Patent number: 6437113Abstract: The invention provides methods and compositions relating to Suppressor of Death Domain (SODD) proteins which regulate cellular signal transduction and transcriptional activation, and related nucleic acids. The polypeptides may be produced recombinantly from transformed host cells from the disclosed SODD encoding nucleic acids or purified from human cells. The invention provides isolated SODD hybridization probes and primers capable of specifically hybridizing with the disclosed SODD genes, SODD-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.Type: GrantFiled: March 5, 1998Date of Patent: August 20, 2002Assignee: Tularik Inc.Inventors: David V. Goeddel, Yingping Jiang
-
Patent number: H2181Abstract: A method for producing tissue plasminogen activator (t-PA) in eukaryotic host cells is disclosed. Enhanced levels of t-PA production are obtained by co-amplification of the t-PA gene through treatment of cultures transformed with mutant or wild-type DHFR with methotrexate.Type: GrantFiled: February 28, 1991Date of Patent: February 6, 2007Assignee: Genentech, Inc.Inventors: Arthur D. Levinson, Diane Pennica, William J. Kohr, Gordon A. Vehar, David V. Goeddel, Elizabeth M. Yelverton, Christian C. Simonsen